The R&D Tax Rule Just Changed Again — Here's What Applies Now
If your business pays people to build software, develop new products, or run engineering and product-testing work, the tax code's treatment of those costs has been unstable for a few years — and it just changed again. The One Big Beautiful Bill Act (OBBBA) created a new section of the tax code, IRC §174A, that restores full current-year deductibility for domestic research and experimentation (R&E) expenses. A related small-business relief provision let qualifying businesses retroactively fix their 2022-2024 returns under the new rule — but per IRS guidance, that window closed on July 6, 2026.
Here's what the rule actually says now, who it affects, and what to know if you missed the retroactive window.
What Changed, and Why It Matters
Before 2022, businesses could generally deduct domestic research and experimentation costs in the year they were paid or incurred — a straightforward current-year expense. A provision in the 2017 Tax Cuts and Jobs Act changed that starting with tax years beginning after December 31, 2021: per IRS interim guidance, domestic R&E costs had to be capitalized and amortized over five years instead of deducted immediately (15 years for research performed outside the U.S.). For R&D-heavy small businesses, that meant paying tax on income that had already gone out the door to cover salaries and contractor costs for research work — a real cash-flow hit, since the deduction was stretched out even though the expense was already paid.
OBBBA reverses that for domestic research. Under the new IRC §174A, per IRS guidance, for tax years beginning after December 31, 2024:
- Domestic R&E costs are deductible in the year paid or incurred — back to the pre-2022 treatment, or
- A business may still elect to capitalize and amortize domestic R&E costs, but only over a minimum 60-month period, starting when the benefits of the research are realized (useful if a business wants to smooth the deduction rather than take it all in one year).
- Foreign R&E is not affected by this change. Research performed outside the U.S. still must be capitalized and amortized over 15 years, beginning at the midpoint of the tax year — a meaningfully harsher rule than the domestic treatment, and one businesses with any offshore development work need to keep separate in their records.
For R&E capitalized during the 2022-2024 window under the old mandatory rule, any unamortized balance can be recovered — either fully in the 2025 tax year, or ratably over 2025 and 2026, depending on which method the business elects.
Who This Affects
This applies to any business that incurs qualifying domestic research and experimentation costs — most commonly:
- Software and SaaS companies doing in-house development work
- Manufacturers running product design, testing, or process-improvement R&D
- Biotech, pharma, and med-device businesses conducting research or clinical development
- Engineering and industrial-design firms performing qualified research for clients or their own products
It does not apply to businesses without R&E spending — routine operating expenses, marketing, or general administrative costs aren't affected by this rule regardless of industry.
The Retroactive Window: Already Closed
A special provision let qualified small businesses apply the new §174A rules early — retroactively, to tax years beginning after December 31, 2021 and before January 1, 2025 (in practice, the 2022, 2023, and 2024 tax years). To qualify, a business's average annual gross receipts — combined with any aggregated group — couldn't exceed $31 million, an inflation-adjusted threshold tested against the 2025 tax year specifically.
Eligible businesses that wanted to use this relief had to file amended returns or Administrative Adjustment Requests by the earlier of July 6, 2026, or their normal refund-claim deadline under IRC §6511. That date has now passed. If your business qualified and didn't file by then, this particular retroactive-fix window is closed — the mechanics involved amended returns (Form 1040-X or 1120-X), an accounting-method change (Form 4562, Form 3115), and in some cases R&D credit coordination (Form 6765, Form 3800), which is enough procedural complexity that this is genuinely a "talk to your tax preparer" situation rather than a same-day fix.
The practical takeaway if you missed it: the current-law treatment (full expensing, tax years 2025 forward) still applies to your current and future R&E spending regardless. What you lost is the chance to unwind the 5-year amortization schedule on 2022-2024 research costs early. Ask your tax preparer whether any other mechanism — outside the small-business relief window covered here — might still apply to your specific prior-year filings; that's a more involved question than this piece can answer.
What It Means Going Forward
Starting with the 2025 tax year, a business with domestic R&E spending has an actual choice for the first time since the 2022 mandatory-capitalization rule kicked in:
- Take the full deduction now, if reducing this year's taxable income is the priority — the default, and the option most R&D-heavy small businesses will use.
- Elect the 60-month amortization instead, if there's a reason to spread the deduction — for example, a business expecting a much higher-income year down the road that would make the deduction more valuable later, or a business already carrying a net operating loss where an immediate deduction wouldn't provide much benefit this year. (See our NOL carryforward guide if that's your situation — an 80%-of-income cap applies to NOL usage, which interacts with this choice.)
Either way, this is now a genuine planning decision to walk through with a tax professional each year, not a fixed rule imposed on you.
Financing the Gap Between R&D Spend and Tax Benefit
Even with full current-year expensing restored, there's still a timing gap: you pay for engineering salaries, contractor invoices, and prototyping costs throughout the year, but the tax benefit doesn't show up until you file. For a business investing heavily in product development, that gap can strain cash flow at exactly the wrong moment — mid-project, before revenue from the new product line has started.
A business line of credit is a common way SMBs bridge that kind of timing mismatch — draw against it to cover payroll or contractor costs during a heavy R&D push, then pay it down once revenue (or a tax refund tied to the prior year's research spend) comes in. As covered in What Underwriters Actually Look for on Tax Returns, lenders reviewing a research-heavy business's tax returns will typically want to understand whether R&E costs were expensed or amortized in a given year, since it affects reported taxable income — worth having that answer ready when you apply.
Funding a heavy R&D push?
A business line of credit can bridge the gap between R&D spend and when this year's deduction lands — see your options.
See your funding options →Bottom Line
OBBBA's new IRC §174A restores immediate deductibility for domestic research and experimentation costs for tax years beginning after 2024 — reversing the 5-year capitalization rule that had squeezed R&D-heavy small businesses' cash flow since 2022. A retroactive-election window let qualifying small businesses (under $31M in average gross receipts) fix their 2022-2024 returns early, but that window closed July 6, 2026. Going forward, businesses now choose annually between full expensing and a 60-month amortization election — a real planning decision worth reviewing with a tax professional before you file.
This post is educational and does not constitute tax advice. Consult a qualified tax professional for guidance specific to your business's research expenses and filing history.